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Mitochondria act as ‘sinks’ for Ca2+ signaling, with mitochondrial Ca2+ up-
take linking physiological stimuli to increased ATP production. However, mi-
tochondrial Ca2+ overload can induce a cellular catastrophe by opening of the
mitochondrial permeability transition pore (mPTP). This pore is a large conduc-
tance pathway in the inner mitochondrial membrane that causes bioenergetic
collapse and appears to represent a final common path to cell death in many
diseases. The role of the mPTP as a determinant of disease outcome is best
established in ischemia/reperfusion injury in the heart, brain, and kidney, and
it is also implicated in neurodegenerative disorders and muscular dystrophies.
As the probability of pore opening can be modulated by drugs, it represents
a useful pharmacological target for translational research in drug discovery.
Described in this unit is a protocol utilizing isolated mitochondria to quantify
this phenomenon and to develop a high-throughput platform for phenotypic
screens for Ca2+ dyshomeostasis. C© 2019 The Authors. This is an open access
article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
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INTRODUCTION
As a universal second messenger, Ca2+ plays a critical role in a wide range of cellular pro-
cesses. At rest, intracellular [Ca2+] gradients are tightly regulated; whereas extracellular
[Ca2+] is at 1 mM, cytosolic [Ca2+] ([Ca2+]c) and mitochondrial [Ca2+] ([Ca2+]m)
are maintained at close to 100 nM. This unique electrochemical gradient allows the
low [Ca2+]c to undergo a substantial proportional increase, with a small and therefore
energetically inexpensive absolute change, in response to a stimulus. Such changes in
[Ca2+]c are a fundamental aspect of cell physiology in all tissues, underlying excitation
contraction coupling, secretion, and motility (Denton & McCormack, 1985; Duchen,
1992; Duchen, Leyssens, & Crompton, 1998; Prudent et al., 2016).
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Ca2+ signaling is subverted in multiple pathologies to drive cell death through opening of
the mitochondrial permeability transition pore (mPTP). Although opening of the pore is
triggered primarily by an increase in mitochondrial Ca2+ load, it can also be induced by
oxidative stress. Pore opening leads to enhanced permeability of the inner mitochondrial
membrane (IMM) to solutes of 1.5 kDa, resulting in membrane rupture, bioenergetic
failure, and ultimately cell death. Seminal studies by Crompton and colleagues in the
1980s revealed that pore opening could be inhibited by cyclosporin A (CsA), suggesting
that the mPTP represents a viable drug target (Crompton, Ellinger, & Costi, 1988). The
association of this phenomenon with disease has resulted in attempts to develop targeted
therapies using screening assays to identify compounds that affect mPTP function (Bris-
ton, Selwood, Szabadkai, & Duchen, 2019). Although cell-permeant fluorescent dyes can
assist in capturing mPTP opening in an intact cell, the results obtained can be variable, as
protocols both to induce and to inhibit mPTP opening have proven to be unreliable. mPTP
opening has long been studied in isolated mitochondria through very robust protocols
that rely on measurements of light scattering or fluorescence measurements following
bolus additions of calcium.
In this unit, mitochondrial Ca2+ buffering is measured in isolated mitochondria
(Basic Protocol 1) using a Ca2+-sensing fluorescent extra-mitochondrial dye (Basic
Protocol 2). Often, healthy mitochondrial function is pivotal to Ca2+ uptake, and there-
fore, it is crucial to ensure that the mitochondria are not damaged during isolation.
This unit details several protocols to allow the user to assay the mPTP in isolated
mitochondria. Basic Protocol 1 involves isolation and purification of mitochondria from
a biological sample using differential centrifugation to obtain functional mitochondria
that can buffer Ca2+. Mitochondrial quality and functional integrity can be assessed using
support protocols for the following: measurement of mitochondrial membrane potential
(m), which is essential for Ca2+ uptake, using the fluorescence indicator rhodamine-
123 (Support Protocol 1); measurement of the oxygen consumption rate (OCR) using a
Clark-type electrode (Support Protocol 2); and immunoblotting for various mitochondrial
proteins as an additional surrogate for mitochondrial content and function (Support
Protocol 3). These quality-control procedures are crucial during initial optimization
of the isolation technique. An additional support protocol (Support Protocol 4) details
cryopreservation of mitochondria using an osmolyte, trehalose, often necessary for high-
throughput drug screens of compound libraries where large quantities of mitochondria
might be needed regularly for multiple assays. Finally, Basic Protocol 2 describes a
fundamental experiment to assay the capacity of mitochondria to accumulate Ca2+
using Ca2+-sensitive fluorescent dyes and how this might vary between genotypes or
treatments. The Alternate Protocol allows multiplexing of this approach with assessment
of mitochondrial swelling. A workflow for the protocols is shown in Figure 1.
BASIC
PROTOCOL 1
ISOLATION AND PURIFICATION OF MITOCHONDRIA FROM MOUSE
LIVER USING EXTRACTION AND CENTRIFUGATION
This protocol is used for isolating mitochondria from animal tissue, such as liver, brain,
heart, or muscle. Liver from an adult mouse is specifically employed below. The key
steps include tissue extraction, homogenization, and differential centrifugation.
Materials
Adult C57/BL6J wildtype mouse (aged 3 to 6 months)
Isolation buffer (see recipe) with or without 1 mM phenylmethane sulfonyl fluoride
(PMSF; 0.1 M stock in ethanol; Sigma-Aldrich, 93482-50ML-F), 4°C
Dulbecco’s phosphate-buffered saline (DPBS; Gibco, 14190094), 4°CBhosale and
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Figure 1 Experimental workflow depicting the order in which each protocol, whether basic or
support, needs to be executed. The solid lines indicate pathways that are necessary, whereas
the dashed lines indicate pathways that are optional. The information needed to determine the
appropriate sequence of experiments is specified in further detail in the text.
Dissecting scissors (World Precision Instruments, 14393)
Tweezers (e.g., Style 5, Dumont, 0103-5-PO)
50-ml Falcon tube (Fisher Scientific, 10788561)
100-ml glass beaker
Scale (with 100 g capacity and 0.1 g readability error)
Tissue homogenizer (Potter-Elvehjem Tissue Grinder with PTFE Pestle and Glass
Tube, Kemble Chase, 886000-0023)
Electric hammer drill (Black+Decker, BCD700S1K)
50-ml Oak Ridge ultracentrifuge tubes (Thermo Scientific, 3118-0050))
Ultracentrifuge with temperature control (Beckman Coulter J2-MC High Speed
Centrifuge) and JA-20 fixed-angle rotor (Beckman Coulter, 334831), 4°C
Pierce BCA Protein Assay Kit (Thermo Scientific, 23225)
Falcon 96-well clear plastic plate (VWR, 734-0023)
Microplate reader (e.g., Fluostar Optima, BMG Labtech)
NOTE: The entire procedure should be conducted on ice, using refrigerated equipment
maintained at 4°C, or in a cold room.
NOTE: Please ensure that you follow the appropriate guidelines set by your institution,
in line with national regulations, when handling animals.
1. Sacrifice an adult C57/BL6J wildtype mouse using an institutionally approved pro-
cedure.
In our procedure, we sacrifice the animal using manual cervical dislocation in compliance
with the guidelines set in the Animals (Scientific Procedures) Act 1986, followed by
decapitation using scissors, as this minimizes damage to the mitochondria. For most
experiments, if testing 25 different conditions, the liver from one adult mouse (3 to
6 months of age) is sufficient.
Alternatively, cells could be used. The number of cells needed for mitochondrial isolation
will vary based on cell type. For example, the yield of mitochondria from 10 million HeLa
cells or a fully confluent 10-cm culture dish is500 µg, which is enough for 10 technical
replicates. We suggest isolating a sufficient amount of mitochondria for 12 replicates
for a basic experiment, as shown in Figure 2A, as well as additional mitochondria for
functional validation of the isolation technique.
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Figure 2 Schematic and graphical representation of Support Protocols 1 and 2. (A) Plate map
depicting the minimum conditions required to assessm using rhodamine-123 in dequench mode
in a fluorescence multiwell plate reader. (B) Oxygen consumption rate (OCR) measurements using
isolated mitochondria and an Oroboros instrument. The blue line and left y-axis depict the oxygen
concentration in nmol/ml. The red line and the right y-axis report the slope of the blue line, that is,
the OCR per milligram of protein, in pmol/s/mg. Drug additions are specified in the order that they
should be performed.
2. Place animal on its dorsal side. Cut through abdomen using dissecting scissors and
tweezers. Locate liver, between the ribcage and the gut. Dissect out entire liver,
ensuring that all lobes are removed (Lampl, Crum, Davis, Milligan, & Del Gaizo
Moore, 2015).
3. Place liver in 20 ml ice-cold isolation buffer in a 50-ml Falcon tube on ice as quickly
as possible (<10 min).
4. Transfer liver from the tube to a 100-ml glass beaker. Rinse liver in ice-cold DPBS
by pouring the DPBS on the liver and then carefully decanting it. Submerge washed
tissue in DPBS and mince it with scissors into rice grain–sized pieces.
5. Repeat rinses with DPBS five times, until the blood is removed from the liver.
6. Weigh liver tissue and add isolation buffer with 1 mM PMSF, with the volume in
milliliters equaling twice the tissue’s weight in grams.
For example, use 10 ml isolation buffer for 5 g tissue.
7. Transfer tissue with the isolation buffer into the glass tube of a tissue homogenizer.
Macerate tissue using an electric hammer drill for 10 to 20 plunges to obtain a
uniform homogenate that contains no visible pieces of tissue.
The capacity of the glass tube as well as the corresponding pestle should be determined
based on the volume of the mixture obtained in step 6.
It is important to ensure that the strokes of the drill are slow and even.
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8. Transfer homogenate to a 50-ml Oak Ridge ultracentrifuge tube and centrifuge
10 min at 800 × g, 4°C, to generate a nuclear pellet.
9. Carefully transfer supernatant to another 50-ml ultracentrifuge tube and centrifuge
10 min at 10,300 × g, 4°C, to isolate crude mitochondrial pellet.
The nuclear pellet can be discarded.
10. Pipet off supernatant, carefully resuspend mitochondrial pellet in 1 ml isolation
buffer with 1 mM PMSF, and place on ice.
11. Quantify protein content of the suspension using a Pierce BCA Protein Assay Kit,
a Falcon 96-well clear plastic plate, and a microplate reader.
This step can take between 20 and 45 min.
The Pierce BCA Protein Assay Kit allows quantification of protein content using colori-
metric detection. It relies on copper-ion reduction by proteins, with the reduced copper
ions in turn reacting with bicinchoninic acid to produce the color change; this can be
measured as a change in absorbance at a wavelength of 562 nm in a microplate reader.
The color change follows a linear relationship with the protein concentration under the
conditions described within the kit. The kit provides materials and instructions for setting
up a standard curve to determine the protein concentration of your mitochondrial sample.
Usually, a single liver can produce 4 to 10 mg/ml protein in the mitochondrial suspension
from step 10. It is possible to combine the mitochondria obtained from livers from multi-
ple animals if from the same genotype and/or treatment condition. When performing the
isolation for the first time, that is, for a new source of mitochondria or a new experimental
condition, functional validation of the mitochondria using Support Protocols 1 to 3 is
essential before proceeding to Basic Protocol 2 or the Alternate Protocol. The mitochon-
drial suspension can be stored at 4°C for8 hr after isolation. If mitochondria need to be
preserved for longer, please refer to Support Protocol 4, which describes an alternative
isolation technique for cryopreservation of functional mitochondria. A workflow for the
experimental design is shown in Figure 1.
SUPPORT
PROTOCOL 1
MEASUREMENT OF MITOCHONDRIAL MEMBRANE POTENTIAL
Healthy mitochondria maintain a negative m across the IMM by pumping protons into
the intermembrane space. This requires energy from sequential reduction of components
of the electron transport chain, with oxygen as the final acceptor. This electrochemical
proton gradient is essential for ATP production by ATP synthase. It is also crucial for
electrogenic uptake of Ca2+. Therefore, this mitochondrial property can be assessed
using cationic fluorescent dyes such as TMRM or rhodamine-123. Rhodamine-123 is
used in the protocol detailed below. This protocol can be carried out immediately after
Basic Protocol 1, before proceeding to Basic Protocol 2 or the Alternate Protocol.
Materials
MSK buffer (see recipe) with 10 mM succinate (1 M stock; Sigma-Aldrich, S3674)
and 1 µM rotenone [1 mM stock in dimethyl sulfoxide (DMSO); Sigma-Aldrich,
R8875]
10 mg/ml rhodamine-123 (Sigma-Aldrich, R8004) in ethanol
Mitochondria (see Basic Protocol 1)
1 mM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP;
Sigma-Aldrich, C2920) in ethanol
190-proof ethanol
Deionized water
Fluorescence plate reader (Fluostar Optima, BMG Labtech), including injector and
two pumps Bhosale andDuchen
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96-well black opaque plate (VWR, 734-1663)
37°C incubator
15-ml Falcon tubes (Fisher Scientific, 10263041)
Excel or equivalent software
1. Set temperature of the fluorescence plate reader to 30°C.
2. Prepare 20 ml MSK buffer with 10 mM succinate and 1 µM rotenone (MSK+; see
Basic Protocol 2, step 2).
3. Add 10 mg/ml rhodamine-123 (fluorescent dye) in ethanol to a final concentration
of 10 µg/ml.
Rhodamine-123 is used in ‘dequench’ mode. In short, the cationic dye is loaded into
the mitochondria at a high concentration, causing quenching of the fluorescence, which
reduces the fluorescence intensity. Upon depolarization and loss of ΔΨ m, the dye moves
out of the mitochondria and into the buffer, where it is no longer quenched. Thus, the
fluorescence signal increases in response to a loss of ΔΨ m (Duchen, Surin, & Jacobson,
2003).
4. Resuspend mitochondria in the MSK+ containing rhodamine-123 to a final concen-
tration of 500 µg/ml. Add 45 µl mitochondrial suspension to each well of a 96-well
black opaque plate in triplicate for each condition (see Fig. 2A for an example plate
design) and incubate for 30 min in a 37°C incubator.
5. Prepare two 15-ml Falcon tubes with MSK+ buffer, with one containing 10 µM
FCCP (from 1 mM stock in ethanol) and the other without FCCP (as a vehicle
control).
Five microliters of 10 µM FCCP (final concentration: 1 µM) or the vehicle control is
injected at cycle 5 to depolarize the mitochondria.
6. Clean plate-reader injector with 190-proof ethanol and deionized water before prim-
ing the two pumps with 1 ml of the respective solutions from step 5.
7. Obtain results from samples using the plate reader once every minute until cycle 5.
Continue to measure for five more cycles after addition of FCCP/vehicle control.
The light source is a high-energy xenon lamp. The emission from the excited sample is
collected using a combination optic containing two liquid-filled light guides for measur-
ing fluorescence intensity. An excitation filter of 485 nm (bandpass: 12) is used, and the
emitted light is detected with a side-window photomultiplier tube after passing through
a 520-nm emission filter. Integrated injectors are used for the compound additions.
8. Collect data after completion of the five cycles and plot fluorescence intensities
against time using Excel or equivalent software.
Addition of FCCP should cause an increase in fluorescence intensity measurements due
to depolarization, indicating an intact ΔΨ m at the start. This increase should be absent
from the wells with no mitochondria and those with the vehicle (negative) control added.
SUPPORT
PROTOCOL 2
MEASUREMENT OF OXYGEN CONSUMPTION RATE
Healthy coupled mitochondria utilize oxygen at complex IV of the electron transport
chain to enable ATP production. Therefore, in the presence of appropriate substrates,
an oxygen electrode can be employed to measure the OCR to gauge the health of
mitochondria. An Oroboros Power O2k-Respirometer is used in the protocol below; this
instrument contains two chambers where dissolved oxygen is measured by a Clark-type
polarographic oxygen electrode as an amperometric signal that is in turn converted into
a voltage. The data obtained from this protocol provide an estimate of the efficiency
of oxidative phosphorylation within the isolated mitochondria (Basic Protocol 1), a
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parameter that should remain consistent across different isolations. This protocol can be
used in conjunction with Support Protocol 1 to ascertain the viability of the mitochondria
obtained from Basic Protocol 1.
Materials
Miro5 buffer (see recipe)
Mitochondria (see Basic Protocol 1)
2 M glutamate (Sigma, G1251)
800 mM malate (Sigma-Aldrich, M1000)
1 M succinate (Sigma-Aldrich, S3674)
1 mM rotenone (Sigma-Aldrich, R8875) in DMSO
500 mM adenosine diphosphate (ADP; Sigma, 01905)
5 mM cytochrome c (Sigma-Aldrich, C3131)
5 mM oligomycin complex (Sigma-Aldrich, O4876) in DMSO
1 mM FCCP (Sigma-Aldrich, C2920) in ethanol
5 mM antimycin A (Sigma-Aldrich, A8674) in ethanol
Power O2k-Respirometer (for high-resolution respirometry; Oroboros Instruments,
10023-02), including sensors, Clark-type electrode chambers with stoppers, and
DatLab software
Hamilton syringes (10 µl and 25 µl)
1. Turn on Power O2k-Respirometer. Calibrate sensors in the Clarke-type electrode
chambers using 2 ml Miro5 buffer (respiration medium) to determine the oxygen
saturation at 37°C (see manufacturer’s instructions), with stirring at 750 rpm.
The temperature and stirring can be set using the DatLab software controlling the
respirometer.
2. Add 100 to 300 µg mitochondria to each chamber and close stoppers to create a
closed O2 system.
The amount of mitochondria used for respirometry measurements must be optimized. In
general, ensure that the basal OCR is >20 pmol per second per milliliter per milligram
of protein. Furthermore, the OCR should not be so high as to cause anoxia during the
course of the experiment. Please refer to Figure 2B for an example trace to complement
the following steps.
3. Once the OCR stabilizes (see red line in Fig. 2B; this should take 5 to 10 min), using
Hamilton syringes, add 2 M glutamate (final concentration, 10 mM) and 800 mM
malate (final concentration, 2 mM).
This will achieve State 2, or complex I–linked respiration, which is the OCR due to the
flow of electrons from complex I as glutamate and malate provide electrons to complex I.
Use Hamilton syringes for compound additions in all steps.
4. Add 1 M succinate (final concentration, 10 mM) and 1 mM rotenone in DMSO
(final concentration, 1 µM) to chambers.
This will result in complex II–linked respiration, as rotenone inhibits complex I and
succinate bypasses this inhibition and provides electrons to complex II.
5. After the OCR stabilizes, add 500 mM ADP (final concentration, 5 mM) to chambers.
The stable OCR after the addition of ADP provides a measure of State 4. This is the
maximal OCR in the presence of a saturating ADP concentration; that is, State 4 is the
maximum OCR when ADP phosphorylation is coupled with oxygen consumption.
6. Add 5 mM cytochrome c (final concentration, 10 µM) to the respiring mitochondria. Bhosale and
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The integrity of the outer mitochondrial membrane (OMM) is tested by observing the
effect of cytochrome c addition on the OCR and comparing this OCR to State 4 respiration.
An increase of <10% indicates an intact OMM. This is an important step in the functional
validation of the mitochondrial isolation technique.
7. Add 5 mM oligomycin complex in DMSO (final concentration, 5 µM).
This step inhibits ATP synthase, thereby identifying the OCR required for ATP production.
A substantial decrease in the OCR indicates an intact IMM, with minimal leakage of
protons across this barrier, and identifies the rate of oxygen consumption required to
sustain ATP turnover.
8. Titrate FCCP (sequential additions of 0.5 µM from a stock of 1 mM FCCP in
ethanol) until maximal uncoupled respiration is attained. Add 5 mM antimycin A, a
complex III inhibitor, in ethanol to a final concentration of 2.5 µM to determine the
non-mitochondrial OCR.
9. Analyze data using the DatLab software after acquisition.
In brief, the average value of the OCR (see red line in Fig. 2B) after stabilization following
drug addition can be extracted, and thus, the effect of the drugs can be compared across
different isolations.
These assay procedures should be conducted routinely to ensure consistent and accurate
mitochondrial isolation, such as every 3 to 5 isolations. A representative trace with
expected values is shown in Figure 2B. In particular, ΔΨ m and the State 4 OCR should
be reproducible across the preparations from the same mitochondrial source on different
days, that is, within a 10% error margin.
SUPPORT
PROTOCOL 3
IMMUNOBLOTTING FOR MITOCHONDRIAL PROTEINS
This protocol summarizes a procedure to quantify mitochondrial proteins using im-
munoblotting, thus validating the mitochondrial isolation (Basic Protocol 1) by probing
for mitochondrially enriched proteins. As loss of cytochrome c from the mitochondria
indicates a ruptured OMM, it is possible to diagnose problems with isolation by quan-
tifying the levels of cytochrome c retained in the mitochondrial pellet. Other proteins
that can be investigated by immunoblotting include TOM20, VDAC (OMM), subunits
of the components of the electron transport chain, and subunits of ATP synthase. Shown
below are a few key steps for western blotting; this procedure can be adapted for different
equipment and reagents.
Materials
Mitochondria (see Basic Protocol 1)
NuPAGE LDS Sample Buffer (4×; Invitrogen, NP0008) with 5% (v/v)
β-mercaptoethanol (Sigma, M6250)
Protein standards (Precision Plus Protein Kaleidoscope Prestained Protein
Standards, Bio-Rad, 1610375)
NuPAGE 4-12% Bis-Tris Protein Gel (Invitrogen, NP0321BOX)
NuPAGE MOPS SDS Running Buffer (Invitrogen, NP0001)
Immobilon-P PVDF membrane (Millipore, IPVH00010)
Methanol
NuPAGE Transfer Buffer (Invitrogen, NP0006) with 20% (v/v) methanol
5% (w/v) skim milk (Millipore, 1153630500) in TBS-T (see below)
Primary antibody (recommended: anti–cytochrome c, Abcam, ab13575;
anti-VDAC1, Abcam, ab15895; anti-TOM20, Santa Cruz Biotechnology,
sc-136211; Total OXPHOS Rodent WB Antibody Cocktail, Abcam, ab110413;
ensure that species origin of antibody is compatible with experimental setup)
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Tris-buffered saline (TBS; see recipe) with 0.1% (v/v) Tween-20 (Sigma, P9416)
(TBS-T)
Horseradish peroxidase (HRP)–conjugated IgG secondary antibody (Sigma, A9044
or A0545)
Chemiluminescent reagent (e.g., Luminata Forte Western HRP substrate, Merck
Millipore, WBLUF0100)
1.5-ml Eppendorf tube
50°C heating block
Protein gel electrophoresis chamber system (XCell SureLock Mini-Cell, Thermo
Fisher, EI0001)
Power supply (e.g., PowerPac HC High-Current Power Supply, Bio-Rad, 1645052)
Semi-dry blot transfer system (Novex Semi-Dry Blotter, Invitrogen, SD1000)
Blot imaging system (ChemiDoc XRS+ System with Image Lab Software,
Bio-Rad, 1708265)
ImageJ2 software (National Institutes of Health)
1. For each sample, heat 50 μg mitochondria in NuPAGE LDS Sample Buffer with 5%
β-mercaptoethanol in a 1.5-ml Eppendorf tube for 5 min in a 50°C heating block for
each sample.
The sample buffer is supplied as a 4× stock, and the volume needed will be determined
by the volume of mitochondrial suspension used.
Critically, a lower temperature is used to preserve the structure of target epitopes of the
mitochondrial proteins.
2. Load samples and protein standards into the wells of a NuPAGE 4-12% Bis-Tris
Protein Gel immersed in NuPAGE MOPS SDS Running Buffer and separate proteins
using a protein gel electrophoresis chamber system and a power supply according
to the manufacturers’ instructions.
Ideally, the gel is run at 150 V for 45 min (the dye front should have run 80% down the
gel) before moving on to step 3. The same mitochondrial sample can be run in multiple
wells so that multiple primary antibodies can be used to probe for different proteins. The
user should probe for cytochrome c at a minimum as a measure of an intact OMM in the
mitochondria in the suspension.
3. Activate an Immobilon-P PVDF membrane with methanol for 1 min. Transfer
proteins from the gel to the PVDF membrane in NuPAGE Transfer Buffer with 20%
methanol using a semi-dry blot transfer system at 20 V for 1 hr.
4. Incubate membrane in 5% skim milk in TBS-T for 1 hr to block the membrane.
5. Incubate membrane with the appropriate primary antibody overnight at 4°C.
6. Wash blots three times with TBS-T for 5 min each before incubating them with the
corresponding HRP-conjugated IgG secondary antibody for 1 hr at room tempera-
ture.
7. Wash blots with TBS-T as in step 6 and visualize protein bands using a chemilumi-
nescent reagent and a blot imaging system.
8. Use densitometry analysis via ImageJ2 software to determine the relative expression
levels of the protein across samples.
Expression levels of the mitochondrial proteins listed above can be instrumental in
functional validation of the isolation technique. In particular, one should expect sufficient
detection of cytochrome c and little fluctuation between expression levels of other proteins
across different isolations. It is advisable to store some protein samples from isolations
for which the results from Support Protocols 1 and 2 and the main assay in Basic Protocol
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2 were satisfactory as a positive control in comparison of protein levels. Immunoblotting
can also provide a parallel investigation to identify underlying causes of differences in
ΔΨ m, the OCR, or Ca2+ retention capacity. Together, Support Protocols 1 to 3 provide
both quality-control checks and additional assessment of mitochondrial physiology.
SUPPORT
PROTOCOL 4
CRYOPRESERVATION OF ISOLATED MITOCHONDRIA
Because of the time needed and batch-to-batch variability, the mitochondria isolation
procedure (Basic Protocol 1) can be the rate-limiting step in high-throughput assessment
of mitochondrial permeability transition. Long-term storage of isolated mitochondria is
advisable to improve assay efficiency and consistency. Because freeze-thaw cycles can
disrupt both the OMM integrity of mitochondria and bioenergetic function, cryopreserva-
tion of mitochondria with intact OMM integrity and biological functions is accomplished
using trehalose, a naturally occurring osmolyte (Yamaguchi et al., 2007). Using mito-
chondria isolated as described in Basic Protocol 1, execute the protocol described below
to prepare tissue for long-term storage and future use.
Additional Materials (also see Basic Protocol 1)
Wash buffer (see recipe), 4°C
Homogenization buffer (see recipe) with cOmplete Protease Inhibitor, 4°C (Roche,
04693159001)
Liquid nitrogen
1. Place tissue (or cells; see Basic Protocol 1, step 1) in ice-cold wash buffer in a
100-ml glass beaker and mince with dissecting scissors.
2. Wash tissue with wash buffer three times to remove blood.
3. Drain wash buffer and replace it with ice-cold homogenization buffer with cOmplete
Protease Inhibitor. Homogenize using a tissue homogenizer as described in step 7 of
Basic Protocol 1, once again using a volume in milliliters equaling twice the tissue’s
weight in grams.
4. Transfer homogenate to a 50-ml Oak Ridge ultracentrifuge tube and centrifuge
10 min at 800 × g, 4°C, to remove the nuclear pellet.
5. Centrifuge supernatant 10 min at 10,300 × g, 4°C, to obtain the crude mitochondrial
pellet.
6. Wash mitochondrial pellet by adding the same volume of homogenization buffer as
in step 3 and repeating step 5.
7. Resuspend pellet in 1 ml homogenization buffer and determine protein concentration
using a Pierce BCA Protein Assay Kit (see Basic Protocol 1, step 11).
8. Using liquid nitrogen, snap freeze mitochondrial suspension at a concentration of
50 mg protein/ml in homogenization buffer and store frozen samples at −80°C for
7 months (Briston et al., 2016).
For subsequent use, thaw the mitochondria at 37°C in a water bath and maintain them
on ice until functional analysis.
INVESTIGATION OF CALCIUM RETENTION CAPACITY OF
MITOCHONDRIA
BASIC
PROTOCOL 2
Investigation of Calcium Retention Capacity of Mitochondria as a Function of
Amount of Ca2+ Buffered Until Permeability Transition
This protocol is designed to determine the capacity of the isolated mitochondria (Ba-
sic Protocol 1) to accumulate Ca2+ until the mPTP opens. Temporal fluorescenceBhosale andDuchen
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Figure 3 Assessment of the minimum conditions needed to determine the Ca2+ retention capac-
ity of the isolated mitochondria, performed in triplicate. The mitochondria-free condition provides a
measure of the total Ca2+ added, and the Ca2+-free addition helps define background fluctuations.
Cyclosporin A is a cyclophilin D–dependent inhibitor of mitochondrial permeability transition pore
opening, and dimethyl sulfoxide (DMSO) is the vehicle control for the cyclosporin A. A positive
control for pore inhibition, such as cyclosporin A, is needed when using the assay for identifying
drug candidates.
measurements of Ca2+-sensing dyes in the extra-mitochondrial buffer provide a simple
and robust readout. An increase in fluorescence intensity in response to Ca2+ addition
is closely followed by a decrease in fluorescence intensity as a result of an increase in
mitochondrial Ca2+ uptake. Sequential additions of Ca2+ ultimately reach a threshold
that results in opening of the mPTP, failure of the mitochondria to accumulate addi-
tional Ca2+, and Ca2+ release from the mitochondria. This results in a rapid increase in
fluorescence intensity. This protocol uses a fluorescence plate reader with an integrated
injector system for adding sequential Ca2+ pulses. For the purposes of drug or phenotypic
screening, we recommend using CsA as a positive control for pore inhibition.
Materials
MSK buffer (see recipe)
1 M succinate (Sigma-Aldrich, S3674)
1 mM rotenone (Sigma-Aldrich, R8875) in DMSO (Sigma-Aldrich, D8418)
1 mM Fluo-5N (Invitrogen, 14203) in DMSO (Sigma-Aldrich, D8418)
Calcium chloride (CaCl2)
190-proof ethanol
Deionized water
Mitochondria (see Basic Protocol 1)
Fluorescence plate reader (Fluostar Optima, BMG Labtech), including integrated
injector and pump
15-ml Falcon tube (Fisher Scientific, 10263041)
96-well clear plastic plate (VWR, 734-0023)
Excel or equivalent software
1. Set temperature of the fluorescence plate reader to 30°C.
2. Prepare MSK buffer supplemented with 10 mM succinate (stock concentration,
1 M) and 1 µM rotenone (stock concentration, 1 mM in DMSO) (MSK+) to energize
the mitochondria and allow electrogenic mitochondrial Ca2+ uptake.
We recommend using 20 ml MSK+ for a basic experiment, as described in Figure 3, and
scaling up as needed for additional conditions.
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Figure 4 Protocol when using a BMG Labtech Fluostar with an injection every 10 cycles, be-
ginning from cycle 5. This sequence is repeated three times, using the inbuilt script mode, to
administer a total of 12 Ca2+ injections.
Succinate acts as a substrate for complex II, and rotenone inhibits complex I, thereby
preventing reverse electron transfer through complex I and blocking accumulation of
oxaloacetate, a known inhibitor of complex II activity.
3. Add 1 mM Fluo-5N (fluorescent dye) in DMSO to the MSK+ to a final concentration
of 1 µM.
4. In a 15-ml Falcon tube, prepare a 100 µM CaCl2 solution in the Fluo-5N-containing
MSK+.
A single 10-µl sample of 100 µM CaCl2 is added beginning at cycle 5, and this is
repeated every 10 cycles thereafter for a total of 12 additions (Fig. 4). This results in
incremental accumulation of10µM Ca2+
.
Please note that the capacity of mitochondria
to accumulate Ca2+ can vary based on the source of the mitochondria, that is, different
tissues or cell lines, and the concentrations of the Ca2+ additions should be titrated
accordingly to allow resolution of pore opening between controls and treatments that
delay pore opening. This step can be performed in a pilot experiment, where ideally
a concentration that causes pore opening between the third and ninth Ca2+ additions
should be used.
5. Clean integrated injector of the plate reader with 190-proof ethanol and deionized
water before priming the pump with 1 ml of the CaCl2 solution.
6. Resuspend mitochondria in the MSK+ containing Fluo-5N from step 3 to a final
protein concentration of 500 µg/ml. Add 100 µl mitochondrial suspension to each
well of a 96-well clear plastic plate in triplicate for each condition (Fig. 3).
A basic plate map for running the assay requires four conditions: wells without mito-
chondria, to which Ca2+ pulses are added, to represent the total Ca2+ added; wells
with mitochondria but with no Ca2+ additions for background measurements; wells with
mitochondria and Ca2+ additions to determine mPTP opening under control conditions;
and finally, wells with mitochondria that have been pretreated with the positive control,
CsA (10 mM in DMSO; Tocris, 1101), to isolate the effect of pore inhibition on Ca2+
retention capacity.
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Figure 5 Typical absorbance curves for mitochondria isolated from mouse liver. In this example,
a single bolus of Ca2+ is added (arrow) to trigger Ca2+-induced pore opening. A loss of absorbance
is observed compared to the condition with no Ca2+ addition. Cyclosporin A (CsA) can rescue this
phenotype. Because the swelling assay lacks sensitivity compared to the Ca2+ retention capacity
assay, a subtle difference in pore desensitization might be missed if using this assay alone.
7. Analyze samples with the plate reader, adjusting the gain settings using a well
containing only the CaCl2 solution as a maximum reading.
The light source is a high-energy xenon lamp. The emission from the excited sample is
collected using a combination optic containing two liquid-filled light guides for mea-
suring fluorescence intensity. An excitation filter of 485 nm (bandpass: 12) is used,
and the emitted light is detected with a side-window photomultiplier tube after passing
through a 520-nm emission filter. Integrated injectors are used to perform the Ca2+
additions.
8. Analyze data using a simple spreadsheet in Excel or equivalent software, tracking
the raw data for changes in fluorescence intensity over time. Given that the area
under the curve for each condition represents the total Ca2+ buffered, calculate
mitochondrial Ca2+ uptake as a fraction of the total Ca2+ (‘buffering capacity’)
added:
1 −
((∑n
i=1 condition
) − (∑ni=1 calcium free
))
(∑n
i=1 mitochondria free
)
Following this, perform comparisons to control untreated conditions by quantifying
shift in the Ca2+ threshold for pore opening as a percentage change:
buffering capacity − buffering capacity (untreated)
buffering capacity (untreated) × 100
ALTERNATE
PROTOCOL
Multiplexing of Detection of Ca2+ Dynamics and Mitochondrial Swelling
Mitochondrial permeability transition is accompanied by mitochondrial swelling due to
loss of IMM integrity. This can be measured as a decrease in light scattering. Historically,
this technique was used to identify inhibitors of permeability transition. However, inhi-
bition of mitochondrial Ca2+ uptake can also prevent mitochondrial swelling, resulting
in false positives. Nevertheless, simultaneously measuring absorbance and Ca2+ reten-
tion capacity can help distinguish between inhibitors of mitochondrial Ca2+ uptake and
inhibitors of pore opening.
The experimental setup is the same as that described in Basic Protocol 2 and does
not require additional material. The additional measurement of absorbance is conducted
simultaneously at 540 nm, and the samples would need to be set up in the plate as depicted
in Basic Protocol 2. A decreased sensitivity to permeability transition is indicated by a
reduced loss of absorbance compared to the control (Fig. 5). Pore opening in the Ca2+
retention capacity assay is mirrored by a steep negative gradient in the absorbance curve.
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This assay makes possible the measurement of two aspects of permeability transition:
that is, mitochondrial swelling due to influx of water and unregulated mitochondrial
Ca2+ release. These data provide the user with additional confidence in the results with
little extra effort in setting up the experiment.
REAGENTS AND SOLUTIONS
All solutions should be prepared with deionized water, sterile filtered, and adjusted to pH 7.4.
They should be prepared on the day of the experiment unless otherwise stated.
Homogenization buffer
Compound Final concentration
Trehalose 300 mM
Potassium chloride 10 mM
EGTA 1 mM
EDTA 1 mM
HEPES 25 mM
Bovine serum albumin (BSA) 0.1% (w/v)
Isolation buffer
Compound Final concentration
Mannitol 250 mM
EGTA 0.5 mM
HEPES 5 mM
Miro5 buffer
Compound Final concentration
EGTA 0.5 mM
Magnesium chloride 3 mM
K-lactobionate 60 mM
Potassium phosphate monobasic 10 mM
HEPES 20 mM
Sucrose 110 mM
BSA 0.001% (w/v)
Miro5 can be stored in 50-ml aliquots for 3 months at −20°C. Once thawed, the
pH should be adjusted to 7.4 at 37°C before use.
MSK buffer
Compound Final concentration
Mannitol 75 mM
Sucrose 25 mM
Potassium phosphate monobasic 5 mM
Tris-HCl 20 mM
Potassium chloride 100 mM
BSA 0.1% (w/v)
Tris-buffered saline
Compound Final concentration
Tris-HCl 20 mM
Sodium chloride 150 mM
TBS can be stored 3 months at 4°C.
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Wash buffer
Compound Final concentration
Sucrose 250 mM
Potassium chloride 10 mM
EGTA 1 mM
EDTA 1 mM
HEPES 25 mM
COMMENTARY
Background Information
Mitochondria play a central role in [Ca2+]c
signaling. They accumulate Ca2+ in an electro-
genic manner, mediated by the mitochondrial
calcium uniporter complex (MCU) (Baugh-
man et al., 2011). Increased [Ca2+]m increases
the activity of the three rate-limiting enzymes
of the tricarboxylic acid cycle, which in turn
upregulates the production of NADH. This
subsequently increases the rate of oxidative
phosphorylation and ATP generation by pro-
viding reducing power for the electron trans-
port chain (Griffiths & Rutter, 2009).
The mPTP was initially described in the
1970s by Haworth and Hunter as a high-
conductance pathway in the IMM that col-
lapses m (Haworth & Hunter, 1979; Hunter
& Haworth, 1979; Hunter & Haworth, 1979).
Numerous studies have demonstrated protec-
tion of tissues by CsA, most notably in the con-
text of cardiac reperfusion injury (Andreeva,
Tanveer, & Crompton, 1995; Duchen et al.,
1998; Hausenloy, Duchen, & Yellon, 2003).
Two decades after the initial description
of the phenomenon, cyclophilin D (CypD), a
mitochondrial matrix protein, was identified as
a modulator to pore opening. This was demon-
strated convincingly by in vivo and in vitro
knock-out studies that resulted in mitochon-
dria with an increased tolerance to Ca2+ loads
(Andreeva & Crompton, 1994; Baines et al.,
2005; Basso et al., 2005; Halestrap & David-
son, 1990; Nakagawa et al., 2005; Schinzel
et al., 2005). Nonetheless, the central compo-
nents of the pore have been the subject of much
debate, with proteins found in both the OMM
(VDAC, TSPO) and the IMM (ATP synthase,
ANT, SPG7) proposed as candidates (Alavian
et al., 2014; Beutner, Ruck, Riede, & Brdiczka,
1998; Bonora et al., 2017; Crompton,
Virji, & Ward, 1998; Elustondo et al., 2016;
Giorgio et al., 2017; Giorgio et al., 2013;
Ricchelli, Sileikyte, & Bernardi, 2011; Ruck,
Dolder, Wallimann, & Brdiczka, 1998; Shan-
mughapriya et al., 2015). Currently, there is
significant uncertainty regarding the molecu-
lar composition of the pore (Baines, Kaiser,
Sheiko, Craigen, & Molkentin, 2007; He, Car-
roll, Ding, Fearnley, & Walker, 2017; He, Ford,
et al., 2017; Kokoszka et al., 2004; Ko¨nig et al.,
2016; Sileikyte et al., 2014; Zhou, Marinelli,
Nief, & Faraldo-Go´mez, 2017).
Although it has been suggested that tran-
sient opening of the pore occurs under physio-
logical conditions, most studies have focused
on its involvement in cell death (Korge et al.,
2011). As a result of this work, the mPTP
has been implicated in many disease patholo-
gies associated with necrotic cell death, is-
chemia/reperfusion injury, neurodegenerative
disorders such as Alzheimer’s and Parkin-
son’s diseases, and several forms of mus-
cular dystrophy and myopathy (Devalaraja-
Narashimha, Diener, & Padanilam, 2009; Du
et al., 2008; Dube et al., 2012; Hausenloy et al.,
2003; Javadov et al., 2003; Millay et al., 2008;
Palma et al., 2009; Thomas et al., 2012). The
role of the mPTP has been most thoroughly
documented in ischemia/reperfusion injury,
particularly in tissues with a high metabolic
demand, such as the brain, kidney, liver, and
heart.
Although CypD is a known regulator of the
mPTP and is therefore a druggable target, the
uncertainty surrounding the molecular identity
of the core components has been a significant
hurdle in drug design and downstream valida-
tion. This has also impeded research into the
involvement of the mPTP in disease and pos-
sible therapeutic interventions. Nevertheless,
pharmacological targeting of elements thought
to form the pore has provided positive results
(for a review, see Briston et al., 2019).
As isolated mitochondria lack the physio-
logical context of intact cells and tissues, func-
tional validation of in vitro data in higher-order
systems is needed before selecting a clinical
candidate. Cell-based assays of the mPTP do
not readily lend themselves to high-throughput
drug discovery programs. Among these assays
is the calcein/cobalt technique, which can be
used to probe pore opening at the level of the
single cell. For this assay, cells are pre-loaded
with the fluorescent marker calcein-AM. The
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dye distributes into all compartments, includ-
ing the mitochondria, and is trapped after
de-esterification by nonspecific esterases. The
cytosolic dye is then quenched by a short in-
cubation with Co2+, which enters the cytosol
but cannot enter intact mitochondria, resulting
in calcein-labeled mitochondria. Induction of
mPTP opening by ionophores or oxidative
stress results in quenching of the mitochon-
drial calcein signal as Co2+ enters the matrix
through the now-permeable IMM. The loss of
m following opening of the pore can also
be measured using potentiometric cationic
dyes such as TMRM, JC-1, or rhodamine-123.
The methods used to induce pore opening
can provide a false positive in these assays.
For example, ionophores that transport Co2+
as well as Ca2+ across the IMM quench the
mitochondrial calcein signal without opening
the mPTP (Panel, Ghaleh, & Morin, 2017).
An established inducer of the mPTP, such as
ischemia/reperfusion, which provides more
physiologically relevant induction of the pore
by combining Ca2+ overload and oxidative
stress, might be a better approach for intact
cells. Therefore, the experimental design
and interpretation of results are far more
complex when assaying the mPTP in intact
cells.
Critical Parameters
Source of mitochondria
Mitochondria can be isolated (Basic Pro-
tocol 1) from virtually any tissue, including
cultured cells. When designing the assay, if de-
veloping and testing a hypothesis that probes
mitochondrial function within a tissue of in-
terest, it is important to consider the phys-
iological context. Other challenges, such as
the ability to obtain an adequate yield of or-
ganelles and to access the tissue/cells of in-
terest, influence the choice of isolation tech-
nique. The buffers employed as well as the
instrument settings for differential centrifuga-
tion may be kept constant across different ex-
perimental setups. The ideal number of cells
and/or amount of tissue needed to provide a
sufficient yield must be optimized prior to ini-
tiating experiments. Furthermore, some tissue,
such as muscle and heart, might require an ad-
ditional protease lysis step prior to homoge-
nization, whereas other tissues, such brain or
cultured cells, require gentler homogenization.
The functional integrity of the isolated mito-
chondria can be assessed by the quality-control
assays described in Support Protocols 1
to 3.
Table 1 Candidate Ca2+-Sensitive Fluores-
cent Indicators
Dye Kd
Fluo-5N 90 µM
Fluo-4FF 9.7 µM
Calcium Green-5N 14 µM
Fura-FFa 6 µM
aRatiometric indicators such as Fura-FF provide a better
quantitative measurement of Ca2+ changes while account-
ing for changes in dye loading and/or photobleaching.
Ca2+-sensing fluorescent dyes
Low-affinity cell-impermeant Ca2+ dyes
are essential for correctly measuring the kinet-
ics of mitochondrial Ca2+ uptake and mPTP
opening (Basic Protocol 2 and Alternate Pro-
tocol). Because the Ca2+ retention capacity
of mitochondria can vary across tissues, cell
types, and isolation techniques, the most ap-
propriate dye must be identified for the assay.
Ideally, the Kd of the dye should be in the
micromolar range. Shown in Table 1 are can-
didate Ca2+-sensitive fluorescence indicators.
Appropriate positive controls
It is crucial to include appropriate controls
for assessing mitochondrial permeability
transition in the assay design. CsA is the
gold-standard control (see Basic Protocol 2)
for desensitizing the pore to inducers of pore
opening, thereby delaying CypD-dependent
permeability transition. The contribution of
CypD to pore opening can also be probed by
genetic knock-out or knock-down. However,
CypD inhibition only delays, and does not
abolish, pore opening. The undefined nature of
the pore complex currently makes it difficult
to identify drug targets independent of CypD,
although some exist, such as ER-000444793
(Briston et al., 2016).
Troubleshooting
The isolation technique (Basic Protocol 1)
is often the source of technical errors en-
countered in executing these protocols. Overly
harsh isolation conditions can damage the mi-
tochondria and inhibit mitochondrial Ca2+ up-
take. The quality-control assays described in
Support Protocols 1 to 3, and particularly re-
tention of cytochrome c in the mitochondrial
membrane (Support Protocol 3), are useful for
identifying the optimum conditions for isola-
tion of the mitochondria. Often, organelle iso-
lation from different tissues results in a crude
mitochondrial pellet that can be used in the
assay of interest. However, contamination of
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Figure 6 Concentration-dependent response to cyclosporin A (CsA) in a Ca2+ retention capacity
assay. (A) Samples of 10 µM CaCl2 (arrows) were added every tenth cycle after the initial addition
at cycle 5 (arrows). An increase in fluorescence intensity after each addition is followed by a
steep decline, indicating mitochondrial Ca2+ uptake. (B) Graphical representation of percentage
inhibition as compared to untreated mitochondria.
the mitochondria with other tissue components
(e.g., myelin in brain preparations) can nega-
tively affect mitochondrial function. In such
cases, a Percoll density gradient can be used
to obtain enriched mitochondrial fractions
with improved respiratory properties (Sims &
Anderson, 2008).
Understanding Results
A graphical representation of the raw data
and quantification of pore opening in the pres-
ence of CsA are shown in Figures 6A and 6B,
respectively. The data were analyzed using the
method described in Basic Protocol 2, step 8.
Time Considerations
The experimental workflow mentioned in
Figure 1 requires6 hr of time, which includes
the time required for Basic Protocols 1 and 2.
Basic Protocol 2 alone can take between 45
min and 3 hr, depending on the number of
conditions per plate.
Support Protocols 1 and 2 do not need to be
performed for every single isolation; however,
these take 1 to 2 hr each when attempted.
It is critical that freshly isolated mitochon-
dria are used for Support Protocols 1 and 2 and
Basic Protocol 2, whereas mitochondria can be
stored at −20°C for use in Support Protocol 3.
The time required to complete Support Pro-
tocol 3 varies based on the system used for
immunoblotting, ranging from 4 hr to 3 days
with current technology.
The requirement to use freshly isolated
mitochondria can be circumvented by isolat-
ing mitochondria according to Alternate Pro-
tocol, which allows the user to stop after
protein quantification and proceed on a later
date.
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